Impact of cytomegalovirus serologic status on heart transplantation.
cardiac allograft vasculopathy
cytomegalovirus
heart transplantation
survival
Journal
Journal of cardiac surgery
ISSN: 1540-8191
Titre abrégé: J Card Surg
Pays: United States
ID NLM: 8908809
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
30
03
2020
accepted:
17
04
2020
pubmed:
4
5
2020
medline:
3
11
2020
entrez:
4
5
2020
Statut:
ppublish
Résumé
Cytomegalovirus (CMV) infection has been associated with increased risk of mortality, cardiac allograft vasculopathy, and de novo malignancy following heart transplantation in prior institutional reports. This study examines the impact of the recipient and donor CMV status on heart recipients in the United States. Adult heart transplant recipients were identified in the OPTN registry between 2005-2016. Recipients were stratified based on the recipient (R) and donor (D) CMV serologic status (+/-). The primary endpoint was survival 5-years after transplantation. The secondary endpoint was cardiac allograft vasculopathy 5-years after transplantation. Separate Cox proportional hazards regression models were developed to evaluate independent associations between CMV status and each of the study endpoints. A total of 21 878 recipients met the inclusion criteria. The breakdown of study arms by CMV serologic status was R-/D- = 3412, R+/D- = 4939; R-/D+ = 5230, and R+/D+ = 8,297. Five-year survival estimates were similar across groups (77-79%). CMV status was associated with increased mortality at 5-years (23%-41% increased risk) which was most evident in the first 3 months. The use of valganciclovir was associated with decreased risk of mortality (HR 0.56; 95% CI, 0.52-0.60). The cumulative incidence of cardiac allograft vasculopathy (R-/D- = 31%, R+/D- = 30%, R-/D+ = 31%, and R+/D+ = 30%) was similar across groups. CMV seropositivity at the time of transplantation is associated with increased long-term risk of mortality. Chemoprophylaxis with antivirals seems to mitigate this risk. There was no association with an increased risk of allograft vasculopathy.
Sections du résumé
BACKGROUND
BACKGROUND
Cytomegalovirus (CMV) infection has been associated with increased risk of mortality, cardiac allograft vasculopathy, and de novo malignancy following heart transplantation in prior institutional reports. This study examines the impact of the recipient and donor CMV status on heart recipients in the United States.
METHODS
METHODS
Adult heart transplant recipients were identified in the OPTN registry between 2005-2016. Recipients were stratified based on the recipient (R) and donor (D) CMV serologic status (+/-). The primary endpoint was survival 5-years after transplantation. The secondary endpoint was cardiac allograft vasculopathy 5-years after transplantation. Separate Cox proportional hazards regression models were developed to evaluate independent associations between CMV status and each of the study endpoints.
RESULTS
RESULTS
A total of 21 878 recipients met the inclusion criteria. The breakdown of study arms by CMV serologic status was R-/D- = 3412, R+/D- = 4939; R-/D+ = 5230, and R+/D+ = 8,297. Five-year survival estimates were similar across groups (77-79%). CMV status was associated with increased mortality at 5-years (23%-41% increased risk) which was most evident in the first 3 months. The use of valganciclovir was associated with decreased risk of mortality (HR 0.56; 95% CI, 0.52-0.60). The cumulative incidence of cardiac allograft vasculopathy (R-/D- = 31%, R+/D- = 30%, R-/D+ = 31%, and R+/D+ = 30%) was similar across groups.
CONCLUSIONS
CONCLUSIONS
CMV seropositivity at the time of transplantation is associated with increased long-term risk of mortality. Chemoprophylaxis with antivirals seems to mitigate this risk. There was no association with an increased risk of allograft vasculopathy.
Substances chimiques
Antiviral Agents
0
Valganciclovir
GCU97FKN3R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1431-1438Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
CDC. Cytomegalovirus (CMV) and Congenital CMV Infection. National Center for Immunization and Respiratory Diseases, Division of Viral Diseases. 2019. https://www.cdc.gov/cmv/resources/healthcare-professionals.html. Accessed January 15, 2020.
Rubin R. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA. 1989;261(24):3607-3609.
Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA. 1989;261(24):3561-3566.
Fateh-Moghadam S, Bocksch W, Wessely R, Jäger G, Hetzer R, Gawaz M. Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy. Transplantation. 2003;76(10):1470-1474. https://doi.org/10.1097/01.TP.0000090163.48433.48
Petrakopoulou P, Kübrich M, Pehlivanli S, et al. Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function. Circulation. 2004;110(11 Suppl 1):II207-II212. https://doi.org/10.1161/01.CIR.0000138393.99310.1c
Johansson I, Andersson R, Friman V, et al. Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients. BMC Infect Dis. 2015;15(1):582. https://doi.org/10.1186/s12879-015-1321-1
Desai R, Collett D, Watson CJE, Johnson PJ, Moss P, Neuberger J. Impact of cytomegalovirus on long-term mortality and cancer risk after organ transplantation. Transplantation. 2015;99(9):1989-1994. https://doi.org/10.1097/TP.0000000000000641
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.
Suarez-Pierre A, Zhou X, Fraser CD, et al. Survival and functional status after bridge-to-transplant with a left ventricular assist device. ASAIO J. 2019;65(7):661-667. https://doi.org/10.1097/MAT.0000000000000874
UNOS. UNOS Transplant Pro - Data Collection Forms. https://transplantpro.org/technology/data-collection-forms/. Accessed February 28, 2019.
Leppke S, Leighton T, Zaun D, et al. Scientific Registry of Transplant Recipients: collecting, analyzing, and reporting data on transplantation in the United States. Transpl Rev. 2013;27(2):50-56.
Core Team R. R: A language and environment for statistical computing. 2019. https://www.r-project.org/. Accessed February 28, 2019.
Mabilangan C, Preiksaitis JK, Cervera C. Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients. Transpl Infect Dis. 2019;21(1):e13015. https://doi.org/10.1111/tid.13015